Lilly's 'Triple-G' Drug Retatrutide Delivers More Than Double the Weight Loss of Ozempic in Head-to-Head Diabetes Study
Written by AI from statnews.com's report. Not checked by a person.
Eli Lilly announced that its experimental drug retatrutide more than doubled weight loss compared with Novo Nordisk's Ozempic in an 80-week head-to-head study in people with diabetes.
Eli Lilly reported on October 28, 2026, that its investigational drug retatrutide outperformed Novo Nordisk's Ozempic on both weight loss and blood-sugar control in a large diabetes study. Over 80 weeks, participants on the highest dose of retatrutide lost an average of 20.9% of their body weight, compared with 9.4% for those on Ozempic — more than double. Blood-sugar control was also superior: retatrutide reduced the A1c marker by 2.2 percentage points versus 1.8 percentage points for Ozempic. Importantly, both sets of figures reflect outcomes only for participants who remained on treatment throughout the study, not all who enrolled. Retatrutide is a so-called "triple-G" drug, meaning it mimics three hunger-regulating hormones, whereas current market-leading drugs target only one or two. The results strengthen Lilly's competitive position against Novo Nordisk in the rapidly growing obesity and diabetes drug market, with retatrutide widely seen as a central pillar of the company's next growth phase as it moves toward potential regulatory review.
